Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin with Dual Checkpoint Blockade for Advanced Soft Tissue Sarcomas
NCT04028063Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jan 2020
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of zalifrelimab, botensilimab, balstilimab in soft tissue sarcoma (STS), sponsored by University of Colorado Denver. Started Jan 2020; status: active, not recruiting.
02
Drugs
zalifrelimabbotensilimabbalstilimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04028063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04028063.